Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment.

Animals Autopsy Behavior, Animal / physiology Depressive Disorder, Major / metabolism Disease Models, Animal Female Fluoxetine / pharmacology Humans Macaca mulatta Male Mice Mice, 129 Strain Mice, Inbred C57BL Mice, Knockout Prefrontal Cortex / drug effects Raphe Nuclei / drug effects Receptor, Serotonin, 5-HT1A / metabolism Serotonergic Neurons / drug effects Serotonin / metabolism Serotonin 5-HT1 Receptor Agonists / pharmacology Selective Serotonin Reuptake Inhibitors / pharmacology Sex Characteristics Social Behavior Vesicular Transport Proteins / drug effects

Journal

Journal of psychiatry & neuroscience : JPN
ISSN: 1488-2434
Titre abrégé: J Psychiatry Neurosci
Pays: Canada
ID NLM: 9107859

Informations de publication

Date de publication:
01 09 2020
Historique:
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 27 10 2021
Statut: ppublish

Résumé

Altered function of serotonin receptor 1A (5-HT1AR) has been consistently implicated in anxiety, major depressive disorder and resistance to antidepressants. Mechanisms by which the function of 5-HT1AR (expressed as an autoreceptor in serotonergic raphe neurons and as a heteroreceptor in serotonin [5-HT] projection areas) is altered include regulation of its expression, but 5-HT1AR trafficking may also be involved. We investigated the consequences of the lack of Yif1B (the 5-HT1AR trafficking protein) on 5-HT neurotransmission in mice, and whether Yif1B expression might be affected under conditions known to alter 5-HT neurotransmission, such as anxious or depressive states or following treatment with fluoxetine (a selective serotonin reuptake inhibitor) in humans, monkeys and mice. Compared with wild-type mice, Yif1B-knockout mice showed a significant decrease in the forebrain density of 5-HT projection fibres and a hypofunctionality of 5-HT1A autoreceptors expressed on raphe 5-HT neurons. In addition, social interaction was less in Yif1B-knockout mice, which did not respond to the antidepressant-like effect of acute fluoxetine injection. In wild-type mice, social defeat was associated with downregulated Yif1B mRNA in the prefrontal cortex, and chronic fluoxetine treatment increased Yif1B expression. The expression of Yif1B was also downregulated in the postmortem prefrontal cortex of people with major depressive disorder and upregulated after chronic treatment with a selective serotonin reuptake inhibitor in monkeys. We found sex differences in Yif1B expression in humans and monkeys, but not in mice under the tested conditions. These data support the concept that Yif1B plays a critical role in 5-HT1AR functioning and brain 5-HT homeostasis. The opposite changes in its expression observed in anxious or depressive states and after therapeutic fluoxetine treatment suggest that Yif1B might be involved in vulnerability to anxiety and depression, and fluoxetine efficacy.

Sections du résumé

Background
Altered function of serotonin receptor 1A (5-HT1AR) has been consistently implicated in anxiety, major depressive disorder and resistance to antidepressants. Mechanisms by which the function of 5-HT1AR (expressed as an autoreceptor in serotonergic raphe neurons and as a heteroreceptor in serotonin [5-HT] projection areas) is altered include regulation of its expression, but 5-HT1AR trafficking may also be involved.
Methods
We investigated the consequences of the lack of Yif1B (the 5-HT1AR trafficking protein) on 5-HT neurotransmission in mice, and whether Yif1B expression might be affected under conditions known to alter 5-HT neurotransmission, such as anxious or depressive states or following treatment with fluoxetine (a selective serotonin reuptake inhibitor) in humans, monkeys and mice.
Results
Compared with wild-type mice, Yif1B-knockout mice showed a significant decrease in the forebrain density of 5-HT projection fibres and a hypofunctionality of 5-HT1A autoreceptors expressed on raphe 5-HT neurons. In addition, social interaction was less in Yif1B-knockout mice, which did not respond to the antidepressant-like effect of acute fluoxetine injection. In wild-type mice, social defeat was associated with downregulated Yif1B mRNA in the prefrontal cortex, and chronic fluoxetine treatment increased Yif1B expression. The expression of Yif1B was also downregulated in the postmortem prefrontal cortex of people with major depressive disorder and upregulated after chronic treatment with a selective serotonin reuptake inhibitor in monkeys.
Limitations
We found sex differences in Yif1B expression in humans and monkeys, but not in mice under the tested conditions.
Conclusion
These data support the concept that Yif1B plays a critical role in 5-HT1AR functioning and brain 5-HT homeostasis. The opposite changes in its expression observed in anxious or depressive states and after therapeutic fluoxetine treatment suggest that Yif1B might be involved in vulnerability to anxiety and depression, and fluoxetine efficacy.

Identifiants

DOI: 10.1503/jpn.190134 PMID: 32459080 PMC: PMC7850149
pubmed: 32459080
doi: 10.1503/jpn.190134
pmc: PMC7850149
doi:

Substances chimiques

Serotonin 5-HT1 Receptor Agonists 0
Serotonin Uptake Inhibitors 0
Vesicular Transport Proteins 0
YIF1B protein, human 0
Fluoxetine 01K63SUP8D
Receptor, Serotonin, 5-HT1A 112692-38-3
Serotonin 333DO1RDJY

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-355

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM121334
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103328
Pays : United States

Informations de copyright

© 2020 Joule Inc. or its licensors.

Déclaration de conflit d'intérêts

None declared.

Références

J Neurosci. 2019 Feb 20;39(8):1334-1346
pubmed: 30552180
J Neurosci. 2018 Sep 19;38(38):8200-8210
pubmed: 30093565
Psychopharmacology (Berl). 1992;106(2):261-7
pubmed: 1347954
Neuroscience. 1991;41(2-3):495-505
pubmed: 1714550
Int J Neuropsychopharmacol. 2010 Sep;13(8):1089-101
pubmed: 20392296
J Neurosci. 2005 Sep 7;25(36):8165-72
pubmed: 16148224
Neuropharmacology. 2017 Jan;112(Pt A):198-209
pubmed: 27211253
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:31-38
pubmed: 30876986
J Neurochem. 2014 Apr;129(2):240-8
pubmed: 24517494
J Neurosci. 2014 Apr 2;34(14):4809-21
pubmed: 24695701
Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):141-8
pubmed: 7477436
Neuroscience. 2017 Jul 25;356:78-88
pubmed: 28528967
Brain Res Dev Brain Res. 1997 Feb 20;98(2):185-90
pubmed: 9051259
J Neurosci. 2012 Oct 10;32(41):14227-41
pubmed: 23055492
Psychol Med. 1999 May;29(3):555-67
pubmed: 10405077
J Biol Chem. 2012 Feb 24;287(9):6615-27
pubmed: 22232550
Behav Brain Res. 2006 Feb 28;167(2):328-41
pubmed: 16256213
Psychopharmacology (Berl). 2012 Nov;224(2):313-25
pubmed: 22707231
Prog Neurobiol. 2009 May;88(1):17-31
pubmed: 19428959
J Neurosci. 2004 May 19;24(20):4807-17
pubmed: 15152041
Nat Protoc. 2011 Jul 21;6(8):1183-91
pubmed: 21799487
Br J Pharmacol. 2017 Aug;174(15):2471-2483
pubmed: 28493335
J Psychosom Res. 2010 Mar;68(3):235-43
pubmed: 20159208
Biol Psychiatry. 2007 May 1;61(9):1081-9
pubmed: 16979141
Int J Neuropsychopharmacol. 2009 Mar;12(2):155-68
pubmed: 18561871
Traffic. 2015 Sep;16(9):978-93
pubmed: 26077767
Neurosci Lett. 1989 Apr 24;99(1-2):101-6
pubmed: 2748003
Autism Res. 2017 Jan;10(1):66-77
pubmed: 27478061
Neurosci Biobehav Rev. 2019 Jan;96:219-231
pubmed: 30543906
Eur J Neurosci. 2010 Jul;32(1):18-26
pubmed: 20561047
Curr Protoc Neurosci. 2011 Jan;Chapter 9:Unit9.36
pubmed: 21207368
Brain Res. 1983 Dec 19;289(1-2):109-19
pubmed: 6140982
Eur J Pharmacol. 2008 Oct 10;594(1-3):117-24
pubmed: 18691569
Cereb Cortex. 2017 Jan 1;27(1):509-521
pubmed: 26494800
EMBO J. 2000 Sep 1;19(17):4485-92
pubmed: 10970842
Curr Pharm Des. 2014;20(23):3738-50
pubmed: 24180393
Neurosci Lett. 2011 Oct 3;503(2):83-6
pubmed: 21871532
Biol Psychiatry. 2010 Jan 15;67(2):117-24
pubmed: 19819426
J Clin Psychiatry. 2006;67 Suppl 12:20-6
pubmed: 17092192
Front Pharmacol. 2018 Oct 16;9:1185
pubmed: 30459605
eNeuro. 2018 Feb 6;5(1):
pubmed: 29445767
J Neurosci. 2008 Aug 6;28(32):8063-73
pubmed: 18685031
Brain Res. 2002 May 17;936(1-2):68-75
pubmed: 11988231
Neuroscience. 2016 May 3;321:210-221
pubmed: 26049143
Neuron. 2015 Aug 5;87(3):549-62
pubmed: 26247862
J Am Coll Dent. 2014 Summer;81(3):4-13
pubmed: 25951677
J Psychiatry Neurosci. 2019 Feb 26;44(3):164-176
pubmed: 30807072

Auteurs

Vincent Martin (V)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Lionel Mathieu (L)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Jorge Diaz (J)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Haysam Salman (H)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Jeanine Alterio (J)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Caroline Chevarin (C)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Laurence Lanfumey (L)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Michel Hamon (M)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Mark C Austin (MC)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Michèle Darmon (M)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Craig A Stockmeier (CA)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Justine Masson (J)

From Inserm UMR894, Centre de Psychiatrie et Neuroscience, Paris F-75014 France; Université Paris Descartes, Sorbonne Paris Cité - Paris 5, France (Martin, Mathieu, Diaz, Salman, Alterio, Chevarin, Lanfumey, Hamon, Darmon, Masson); the College of Pharmacy, Idaho State University, Pocatello, ID 83209 USA (Austin); the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216 USA (Stockmeier); and Inserm UMR-S 1270, Paris, France; Sorbonne Université, Science and Engineering Faculty, Paris, France; Institut du Fer à Moulin, Paris, France (Darmon, Masson).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Sciences sociales › Criminologie › Sciences légales › Médecine légale › Autopsie › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement animal › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Composés chimiques organiques › Amines › Propylamines › Fluoxétine › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Souris de souche-129 › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Lobe frontal › Cortex préfrontal › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Rhombencéphale › Myélencéphale › Moelle allongée › Noyaux du raphé › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs sérotoninergiques › Récepteurs de la sérotonine de type 5-HT1 › Récepteur de la sérotonine de type 5-HT1A › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Cellules › Neurones › Neurones sérotonergiques › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Sérotonine › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Agonistes des récepteurs de la sérotonine › Agonistes des récepteurs 5-HT1 de la sérotonine › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Inhibiteurs sélectifs de la recapture de la sérotonine › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Caractères sexuels › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement social › Key role of the 5-HT1A receptor addressing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines du transport vésiculaire › Key role of the 5-HT1A receptor addressing...